Train harder · Free ship $75+ · Gear up now
Login Register
pfizer glp-1 pipeline

pfizer glp-1 pipeline has released promising mid-stage Phase IIb trial data for its obesity treatment, PF-3944. This long-acting injectable demonstrated an impressive 12.3% placebo-adjusted weight loss at 28 weeks with monthly dosing, positioning Pfizer adds small molecule GLP-1

SKU: 47434352845

4.5
USD20.31 USD59.31

Pay in 4 interest-free payments of $5.08 Learn more

Shipping Estimate
USA
  • USA
  • CAN

Ships within 48 hours · Estimated delivery Aug 28 - Sep 2

Description

doi: 10.1016/j.arr.2021.101305

pfizer glp-1 pipeline has released promising mid-stage Phase IIb trial data for its obesity treatment, PF-3944. This long-acting injectable demonstrated an impressive 12.3% placebo-adjusted weight loss at 28 weeks with monthly dosing, positioning Pfizer adds small molecule GLP-1

Without it, even basic tasks can feel overwhelming

pfizer glp-1 pipeline has released promising mid-stage Phase IIb trial data for its obesity treatment, PF-3944. This long-acting injectable demonstrated an impressive 12.3% placebo-adjusted weight loss at 28 weeks with monthly dosing, positioning Pfizer adds small molecule GLP-1

For Women & Men

pfizer glp-1 pipeline has released promising mid-stage Phase IIb trial data for its obesity treatment, PF-3944. This long-acting injectable demonstrated an impressive 12.3% placebo-adjusted weight loss at 28 weeks with monthly dosing, positioning Pfizer adds small molecule GLP-1

It supports your body's natural fat metabolism

pfizer glp-1 pipeline has released promising mid-stage Phase IIb trial data for its obesity treatment, PF-3944. This long-acting injectable demonstrated an impressive 12.3% placebo-adjusted weight loss at 28 weeks with monthly dosing, positioning Pfizer adds small molecule GLP-1

Its common to experience mild side effects, such as nausea or upset stomach, when beginning GLP-1 treatment

pfizer glp-1 pipeline has released promising mid-stage Phase IIb trial data for its obesity treatment, PF-3944. This long-acting injectable demonstrated an impressive 12.3% placebo-adjusted weight loss at 28 weeks with monthly dosing, positioning Pfizer adds small molecule GLP-1

There are no clinical trials demonstrating weight loss from this specific product

pfizer glp-1 pipeline has released promising mid-stage Phase IIb trial data for its obesity treatment, PF-3944. This long-acting injectable demonstrated an impressive 12.3% placebo-adjusted weight loss at 28 weeks with monthly dosing, positioning Pfizer adds small molecule GLP-1
Exchange/Return Notes
  • We offer a 30-day return/exchange service after receiving.
  • Final sale items are not eligible for returns or exchanges.
  • To process your return/exchange, please contact us at [email protected]
  • Please click here for more details>>> Return & Exchange Policy

You may also like

recommand products